Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20357520 | 1.00 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19181047 | 0.96 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL31409102 | 0.96 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19181048 | 0.96 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19180964 | 0.90 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19180965 | 0.90 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19182311 | 0.88 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19182312 | 0.88 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19181596 | 0.88 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19181597 | 0.88 | ERBB2 (1.00) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590516-B1 | ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-07-11 | — | — | US | disclosed |
| EP-3345907-B1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-25 | — | — | US | disclosed |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. , LTD. (JP) | 2018-07-19 | — | — | US | disclosed |
| EP-3345907-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | ZYX, DPYD, ZFX | ERBB2 2137/4885EGFR 2082/4885 |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | ERBB2 1/4885EGFR 5/4885 |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | ERBB2, JAK2, ERBB4 | ERBB2 1/4885EGFR 5/4885 |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | ZYX, DPYD, ZFX | ERBB2 2137/4885EGFR 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.